AtaiBeckley stock has delivered a 148.7% return over the last three years, yet its valuation checks flag the shares as expensive rather than a clear bargain.

• A 148.7% three year return puts AtaiBeckley firmly in the spotlight and raises the bar for what future progress needs to justify the current share price.
• The advancing psychedelic pipeline, including BPL-003 in Phase 3 and VLS-01 in Phase 2b for treatment resistant depression, can support high expectations, while takeover speculation and recent insider selling may add uncertainty around how much investors should pay today.
• AtaiBeckley screens as expensive on Simply Wall St's broader checks, with the stock undervalued in 0 of 6 valuation tests, which suggests it is not a clear bargain on traditional metrics.

The issue now is whether AtaiBeckley’s recent gains leave enough valuation support for new investors at current levels.

AtaiBeckley delivered 114.0% returns over the last year. See how this stacks up to the rest of the Pharmaceuticals industry.

Is AtaiBeckley Getting Expensive on Book Value?

P/B is often a useful cross check for a clinical stage company like AtaiBeckley where earnings are not yet the main focus and the balance sheet matters a lot.

AtaiBeckley currently trades at a P/B of 10.5x, compared with about 2.3x for the wider Pharmaceuticals industry and around 5.4x for closer peers. That is a clear premium to both benchmarks, suggesting investors are paying a high price for each dollar of net assets on the balance sheet.

Recent excitement around BPL-003’s Phase 3 program and the supportive FDA guidance for psychedelic trials has helped sentiment, but the current P/B still leaves AtaiBeckley screening as overvalued on this metric relative to sector norms.

On the P/B multiple, AtaiBeckley stock currently looks overvalued compared with both its peers and the broader Pharmaceuticals industry.

See what the numbers say about this price — find out in our valuation breakdown.

The AtaiBeckley Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where AtaiBeckley’s valuation puzzle leaves off by spelling out which future assumptions on growth, margins and earnings would need to hold for the stock to be worth materially more or less than today’s price. Each narrative sets out a fair value as a concrete thesis about AtaiBeckley's business that you can watch over time, and they sit on Simply Wall St's Community page alongside other investor views.

Here is a chance to add your voice to the Simply Wall St community and lay out a numbers based narrative on whether AtaiBeckley's progress with BPL-003 and VLS-01 really supports today's valuation.

Share a clear, data driven case that others can track against future trial results and regulatory milestones to see how well your thesis holds up over time.

Do you think there's more to the story for AtaiBeckley? Head over to our Community to see what others are saying!

The Bottom Line

For now, AtaiBeckley screens as overvalued on traditional market multiples, with its high P/B standing out against both peers and the wider Pharmaceuticals industry. That does not rule out further upside. However, it does mean expectations around BPL-003, VLS-01 and the broader psychedelic pipeline are already built heavily into the price.

The real dividing line between bulls and bears from here is whether AtaiBeckley can deliver trial progress and regulatory milestones strong enough to keep justifying that premium, or whether the market eventually reins in the multiple if the story takes longer to play out than optimists hope.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.